A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumoursNicola Steele, Johann S. de Bono, Anne Rasmussen et al.|Journal of Clinical Oncology|2005Cited by 19
Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)Silvia Novello, Giorgio V. Scagliotti, Anna K. Nowak et al.|Annals of Oncology|2017Cited by 0